Prelude Therapeutics, Inc. (PRLD)
3.88
-0.22
(-5.37%)
USD |
NASDAQ |
Oct 30, 16:00
3.923
+0.04
(+1.11%)
After-Hours: 20:00
Prelude Therapeutics Enterprise Value : 175.35M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 175.35M |
| October 29, 2026 | 192.90M |
| October 28, 2026 | 196.09M |
| October 27, 2026 | 175.35M |
| October 26, 2026 | 160.99M |
| October 23, 2026 | 155.41M |
| October 22, 2026 | 153.02M |
| October 21, 2026 | 157.01M |
| October 20, 2026 | 147.44M |
| October 19, 2026 | 136.27M |
| October 16, 2026 | 125.90M |
| October 15, 2026 | 130.69M |
| October 14, 2026 | 123.51M |
| October 13, 2026 | 149.83M |
| October 12, 2026 | 164.18M |
| October 09, 2026 | 176.15M |
| October 08, 2026 | 175.35M |
| October 07, 2026 | 171.36M |
| October 06, 2026 | 169.77M |
| October 05, 2026 | 166.58M |
| October 02, 2026 | 158.60M |
| October 01, 2026 | 168.17M |
| September 30, 2026 | 177.74M |
| September 29, 2026 | 181.73M |
| September 28, 2026 | 177.74M |
| Date | Value |
|---|---|
| September 25, 2026 | 174.95M |
| September 24, 2026 | 184.12M |
| September 23, 2026 | 209.65M |
| September 22, 2026 | 252.71M |
| September 21, 2026 | 240.75M |
| September 18, 2026 | 254.31M |
| September 17, 2026 | 230.38M |
| September 16, 2026 | 222.41M |
| September 15, 2026 | 226.40M |
| September 14, 2026 | 231.98M |
| September 11, 2026 | 231.98M |
| September 10, 2026 | 238.36M |
| September 09, 2026 | 271.86M |
| September 08, 2026 | 288.61M |
| September 04, 2026 | 301.37M |
| September 03, 2026 | 284.62M |
| September 02, 2026 | 298.97M |
| September 01, 2026 | 303.76M |
| August 31, 2026 | 312.53M |
| August 28, 2026 | 302.16M |
| August 27, 2026 | 371.55M |
| August 26, 2026 | 389.10M |
| August 25, 2026 | 391.49M |
| August 24, 2026 | 381.92M |
| August 21, 2026 | 394.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Q32 Bio, Inc. | 110.52M |
| Intellia Therapeutics, Inc. | 1.382B |
| Twist Bioscience Corp. | 9.502B |
| Beam Therapeutics, Inc. | 1.906B |
| Revolution Medicines, Inc. | 38.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.92M |
| Revenue (Quarterly) | 5.704M |
| Total Expenses (Quarterly) | 19.62M |
| EPS Diluted (Quarterly) | -0.1415 |
| Gross Profit Margin (Quarterly) | 93.81% |
| Profit Margin (Quarterly) | -244.1% |
| Earnings Yield | -20.30% |
| Normalized Earnings Yield | -20.30 |